Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Baumgart

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Infection and Immunity|June 23, 2006
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathwaysA Grabig, D Paclik, C Guzy, et al.
Alimentary Pharmacology & Therapeutics|September 20, 2007
Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitisC Büning, H H-J Schmidt, T Molnar, et al.
Alimentary Pharmacology & Therapeutics|October 8, 2016
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational studyA Stallmach, C Langbein, R Atreya, et al.
Journal of Crohn'S & Colitis|April 16, 2013
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelinesJ Panes, Y Bouhnik, W Reinisch, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Infection and Immunity|June 23, 2006
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathwaysA Grabig, D Paclik, C Guzy, et al.
Alimentary Pharmacology & Therapeutics|September 20, 2007
Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitisC Büning, H H-J Schmidt, T Molnar, et al.
Alimentary Pharmacology & Therapeutics|October 8, 2016
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational studyA Stallmach, C Langbein, R Atreya, et al.
Journal of Crohn'S & Colitis|April 16, 2013
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelinesJ Panes, Y Bouhnik, W Reinisch, et al.
Pageof 3